These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 36729145)
1. Reconsidering "dissociation" as a predictor of antidepressant efficacy for esketamine. Mathai DS; Nayak SM; Yaden DB; Garcia-Romeu A Psychopharmacology (Berl); 2023 Apr; 240(4):827-836. PubMed ID: 36729145 [TBL] [Abstract][Full Text] [Related]
2. Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression. Chen G; Chen L; Zhang Y; Li X; Lane R; Lim P; Daly EJ; Furey ML; Fedgchin M; Popova V; Singh JB; Drevets WC Int J Neuropsychopharmacol; 2022 Apr; 25(4):269-279. PubMed ID: 35022754 [TBL] [Abstract][Full Text] [Related]
3. Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials. Saad Z; Hibar D; Fedgchin M; Popova V; Furey ML; Singh JB; Kolb H; Drevets WC; Chen G Int J Neuropsychopharmacol; 2020 Dec; 23(9):549-558. PubMed ID: 32367114 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201 [TBL] [Abstract][Full Text] [Related]
5. Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine and esketamine in treatment-resistant depression? A secondary analysis from a randomized controlled trial. Echegaray MVF; Mello RP; Magnavita GM; Leal GC; Correia-Melo FS; Jesus-Nunes AP; Vieira F; Bandeira ID; Caliman-Fontes AT; Telles M; Guerreiro-Costa LNF; Marback RF; Souza-Marques B; Lins-Silva DH; Santos-Lima C; Cardoso TA; Kapczinski F; Lacerda ALT; Quarantini LC Trends Psychiatry Psychother; 2023 Sep; ():. PubMed ID: 37717263 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials. Jones RR; Freeman MP; Kornstein SG; Cooper K; Daly EJ; Canuso CM; Nicholson S Arch Womens Ment Health; 2022 Apr; 25(2):313-326. PubMed ID: 34973081 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965 [TBL] [Abstract][Full Text] [Related]
8. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant. Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant. Floden L; Hudgens S; Jamieson C; Popova V; Drevets WC; Cooper K; Singh J CNS Drugs; 2022 Jun; 36(6):649-658. PubMed ID: 35441931 [TBL] [Abstract][Full Text] [Related]
10. Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD. Williamson D; Turkoz I; Wajs E; Singh JB; Borentain S; Drevets WC Int J Neuropsychopharmacol; 2023 Mar; 26(3):198-206. PubMed ID: 36525338 [TBL] [Abstract][Full Text] [Related]
11. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder". Borentain S; Desai P; Fu DJ; Nancy Chen L; Lane R; Mathews M; Canuso CM J Psychopharmacol; 2023 Aug; 37(8):836-844. PubMed ID: 36218274 [TBL] [Abstract][Full Text] [Related]
12. IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression. Gutierrez G; Swainson J; Ravindran N; Lam RW; Giacobbe P; Karthikeyan G; Kowara A; Do A; Baskaran A; Nestor SM; Kang MJY; Biorac A; Vazquez G Psychiatry Res; 2024 Oct; 340():116125. PubMed ID: 39128167 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. Ochs-Ross R; Daly EJ; Zhang Y; Lane R; Lim P; Morrison RL; Hough D; Manji H; Drevets WC; Sanacora G; Steffens DC; Adler C; McShane R; Gaillard R; Wilkinson ST; Singh JB Am J Geriatr Psychiatry; 2020 Feb; 28(2):121-141. PubMed ID: 31734084 [TBL] [Abstract][Full Text] [Related]
15. Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial. Mello RP; Echegaray MVF; Jesus-Nunes AP; Leal GC; Magnavita GM; Vieira F; Caliman-Fontes AT; Telles M; Guerreiro-Costa LNF; Souza-Marques B; Bandeira ID; Santos-Lima C; Marback RF; Correia-Melo FS; Lacerda ALT; Quarantini LC J Psychiatr Res; 2021 Jun; 138():576-583. PubMed ID: 33991996 [TBL] [Abstract][Full Text] [Related]
16. Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine. Borentain S; Gogate J; Williamson D; Carmody T; Trivedi M; Jamieson C; Cabrera P; Popova V; Wajs E; DiBernardo A; Daly EJ Int J Methods Psychiatr Res; 2022 Dec; 31(4):e1927. PubMed ID: 35749277 [TBL] [Abstract][Full Text] [Related]
17. The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder. Daly EJ; Turkoz I; Salvadore G; Fedgchin M; Ionescu DF; Starr HL; Borentain S; Trivedi MH; Thase ME; Singh JB Depress Anxiety; 2021 Nov; 38(11):1120-1130. PubMed ID: 34293233 [TBL] [Abstract][Full Text] [Related]
18. Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data. Nijs M; Wajs E; Aluisio L; Turkoz I; Daly E; Janik A; Borentain S; Singh JB; DiBernardo A; Wiegand F Int J Neuropsychopharmacol; 2020 Jul; 23(7):426-433. PubMed ID: 32270176 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting. Santucci MC; Ansari M; Nikayin S; Radhakrishnan R; Rhee TG; Wilkinson ST J Clin Psychiatry; 2024 Oct; 85(4):. PubMed ID: 39361411 [No Abstract] [Full Text] [Related]
20. Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression. Targum SD; Daly E; Fedgchin M; Cooper K; Singh JB J Psychiatr Res; 2019 Apr; 111():68-73. PubMed ID: 30685564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]